Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This acquisition will significantly reinforce Grifols’ industry capabilities by enhancing its plasmaderived medicines access, pipeline Biotest is leading clinical trials on plasma-derived fibrinogen (BT524) to treat congenital and acquired disorders.
Lead Product(s): BT524
Therapeutic Area: Genetic Disease Product Name: BT524
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Grifols International
Deal Size: $1,281.5 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 17, 2021